Published in
Springer, Investigational New Drugs, 4(38), p. 1156-1165, 2019
DOI: 10.1007/s10637-019-00869-2
Links
Tools
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors
Journal article published in 2019 by
Albiruni R. Abdul Razak,
Wilson H. Miller,
Geoffrey L. Uy 
,
Steven Blotner,
Anne-Marie Young,
Brian Higgins,
Lin-Chi Chen,
Lia Gore
,
Steven Blotner,
Anne-Marie Young,
Brian Higgins,
Lin-Chi Chen,
Lia Gore
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 